Moser 2013 (Vienna): Why a 15-Month Follow-Up Changed What We Thought About Hypnotherapy Durability

What the study actually tested (and why 'refractory IBS' matters)

Moser and colleagues ran a single-center randomized controlled trial out of the Medical University of Vienna, recruiting from the gastroenterology and psychosomatic medicine services. The published paper is Moser G, Tragner S, Gajowniczek EE, Mikulits A, Michalski M, Kazemi-Shirazi L, Kulnigg-Dabsch S, Fuhrer M, Ponocny-Seliger E, Dejaco C, Miehsler W. 'Long-term success of GUT-directed group hypnosis for patients with refractory irritable bowel syndrome: a randomized controlled trial.' American Journal of Gastroenterology 2013; 108(4): 602 to 609.

The enrolled population is the design choice that most shapes how to read the results. Moser 2013 did not enroll mild, newly-diagnosed, or treatment-naive IBS patients. The trial enrolled 100 patients meeting Rome III criteria for IBS who had been refractory to at least one year of standard medical treatment. 'Refractory' in this context means the patient had already tried at least one of the standard pharmacological or dietary interventions for IBS and not achieved meaningful symptom control. This matters in two ways.

First, refractory enrichment makes a positive responder rate more clinically meaningful. If 60 percent of refractory patients respond to an intervention after standard care has failed, that is a more important clinical finding than 60 percent response in a treatment-naive population (where placebo and natural history account for a larger fraction of apparent benefit). The intervention is being asked to do something harder.

Second, refractory enrichment limits generalization to milder populations. A patient with newly-diagnosed mild IBS may not need the protocol Moser tested, may respond to first-line interventions that the trial population had already failed, and may have a lower baseline severity from which to demonstrate the same magnitude of improvement. Generalizing the responder rate downward to milder IBS is not directly supported by this trial.

Patients were randomized 2:1 to one of two arms. The 2:1 allocation (more patients to the experimental arm than the control arm) is unusual in modern trials and reflects a deliberate design choice by the Moser group: it concentrates statistical power on detecting an effect within the experimental arm at the cost of statistical power on the control arm. Approximately 64 patients were assigned to the gut-directed hypnotherapy (GDH) arm and approximately 36 to the supportive talks active control arm. The Vienna group's reasoning, articulated in the methods section, was that the experimental arm needed adequate power to detect both end-of-treatment and long-term responder rates.

The GDH arm received 10 weekly sessions of gut-directed group hypnotherapy. Sessions were 45 minutes, delivered to groups of 6 to 10 patients by an experienced clinician trained in the gut-directed protocol. The protocol was adapted from the Manchester Protocol originally developed by Whorwell in the 1980s (see the Whorwell 1984 RCT deep dive for the protocol's origin), with adaptations for group delivery: shared induction, group-paced visualization, and standardized home-practice audio recordings between sessions. The supportive talks active control arm received 10 weekly sessions of equivalent length and group size, focused on IBS education, lifestyle discussion, and group support without hypnotic technique. Both arms continued their existing pharmacological treatment as usual throughout the trial.

Primary outcome was the IBS Impact Scale (IBS-IS), a validated patient-reported symptom and quality-of-life instrument used widely in IBS research. Secondary outcomes included a structured symptom diary, well-being score, and depression/anxiety scoring. A patient was classified as a responder if they achieved a predefined improvement threshold on IBS-IS and symptom diary scores.

Prospective assessment timepoints were end of 10-week treatment (3 months from baseline), 12-month follow-up, and 15-month follow-up. The 15-month horizon is what makes this trial distinctive. Most IBS intervention trials assess at 3 to 6 months. Peters 2016, for example, used 6-month follow-up (see the Peters 2016 deep dive). Moser 2013 is the longest prospective RCT follow-up in the gut-directed hypnotherapy literature to date.

The headline finding: durable benefit at 15 months

At end of 10-week treatment (3-month assessment), the gut-directed hypnotherapy arm showed significantly greater symptom improvement than the supportive talks active control arm on both the IBS Impact Scale and the symptom diary. This is consistent with prior shorter-duration hypnotherapy trials and is not in itself the trial's distinctive contribution. End-of-treatment response in IBS interventions is common; the question is whether the response persists.

The distinctive findings are at 12 and 15 months.

At 12-month follow-up, the hypnotherapy arm continued to show significantly greater symptom improvement than the active control arm. The treatment effect had not faded between 3 months and 12 months. Patients who had completed the 10-week group hypnotherapy protocol nine months prior were still scoring meaningfully better on the IBS Impact Scale than patients who had completed the 10-week supportive talks protocol over the same window.

At 15-month follow-up, the same pattern held. Roughly 60 percent of the gut-directed hypnotherapy arm met the prespecified responder criterion on the IBS Impact Scale at 15 months. The active control arm showed roughly 25 percent responder rate at the same timepoint. The between-arm difference was statistically significant on the trial's primary analyses.

Why 15 months matters for the gut-directed hypnotherapy literature specifically. Prior to Moser 2013, the longest prospective RCT follow-up in this literature was 6 to 12 months. There was a strong clinical sense, from open audit data (especially Gonsalkorale 2003 in Gut, the 250+ patient Manchester audit with 5-year informal follow-up), that the benefit of the Manchester Protocol persisted long after the protocol ended. But audit data is not RCT data. Gonsalkorale's patients were self-selected, not randomized, and had no concurrent control arm to baseline against. Moser 2013 is the trial that converted 'we think the benefit lasts' into 'in 100 randomized patients with an active matched-attention control, the benefit lasts past one year.'

The wrong way to read this finding. 'Hypnotherapy works for 60 percent of IBS patients at 15 months' is the responder-rate number, but it is not the same as 'hypnotherapy cures 60 percent of IBS patients.' Responder means a predefined improvement threshold on a validated scale, not symptom-free. Some responders still had meaningful symptoms, just at a lower severity than they had at baseline. And the 60 percent number is averaged across a refractory population that had already failed at least one year of standard care, so generalizing it downward to mild IBS is not directly supported.

The right way to read this finding. In a hard-to-treat IBS population that had already failed standard care, a well-defined 10-week group hypnotherapy protocol produced significantly more responders at 15 months than an active matched-attention control. The persistence of the effect at 12 and 15 months is the load-bearing contribution. Most IBS interventions that show 3-month benefit do not show 15-month benefit at this magnitude. The Vienna trial is the principal RCT-grade evidence that gut-directed hypnotherapy effects are durable past one year.

What was different about the group format (and what it sacrifices)

Moser 2013 used a group hypnotherapy format. This was not an arbitrary methodological choice. It was a deliberate clinical and economic choice, and it shapes how the findings should be generalized to your decision in 2026.

What group hypnotherapy is, in this context. Six to ten patients meeting Rome III IBS criteria gather in a clinic room or healthcare-setting group room with a single trained clinician. The session runs for 45 minutes. The clinician delivers a standardized gut-directed hypnotic induction and a shared visualization protocol. Patients are taught to use a home-practice audio recording between sessions. The clinician adapts the script for the group room rather than for the individual patient. Patients hear each other's induction, share an induction tempo, and complete the same visualization simultaneously.

What group hypnotherapy buys, methodologically. The format is dramatically more cost-efficient to deliver than 1-on-1 hypnotherapy. A clinician hour delivered to 8 patients per session produces the same clinical hours but at roughly one-eighth the per-patient cost. For a national health service or a public hospital gastroenterology clinic considering scale-up of gut-directed hypnotherapy, the group format is the version that has any realistic path to being delivered at scale. The Moser group's reasoning, articulated in the discussion section, was that the trial needed to test the version of the intervention that could plausibly be deployed broadly, not just the boutique 1-on-1 version.

What group hypnotherapy sacrifices, clinically. The individualization that a 1-on-1 hypnotherapy session provides is mostly lost in the group format. The clinician cannot adapt the imagery, depth, or pace to a single patient's responsiveness. A patient who needs a slower induction does not get one. A patient whose specific symptom pattern (constipation-predominant versus diarrhea-predominant, abdominal pain versus bloating-dominant) would benefit from imagery tuned to their pattern gets the group-standard imagery instead. A patient who has a difficult moment mid-session has fewer options for the clinician to respond in real time.

The head-to-head 1-on-1 versus group comparison. To my knowledge, there is no large head-to-head randomized trial directly comparing 1-on-1 gut-directed hypnotherapy to group gut-directed hypnotherapy with the same protocol, same clinician training, and same patient population. What we have instead are within-format trials: Whorwell 1984 and Gonsalkorale 2003 are the principal evidence for the 1-on-1 Manchester Protocol, Moser 2013 is the principal RCT evidence for the group adaptation. The implicit comparison across studies suggests both formats can produce meaningful symptom benefit, but the magnitude and durability cannot be directly compared without a head-to-head trial.

What this means for a patient deciding between formats in 2026. If your goal is to replicate the Moser 2013 evidence exactly, you should be seeking a 10-session group format with a clinician trained in the gut-directed protocol. If your goal is to receive an individualized version of the same evidence-backed protocol family, you should be seeking 1-on-1 sessions with a clinician using a named protocol (Manchester or North Carolina) and ARCH credentials. Most private-practice gut-directed hypnotherapy in Canada in 2026 is delivered 1-on-1, not in groups. The Moser 2013 evidence supports the broader claim that gut-directed hypnotherapy works durably; the specific format you receive in private practice will usually not be the same as the format Moser tested.

How this compares to 1-on-1 individual hypnotherapy outcomes

Comparing Moser 2013 (group format) to the 1-on-1 hypnotherapy literature requires reading across trials with different designs, populations, and outcome instruments. Below is the honest comparison.

Whorwell, Prior, and Faragher 1984 in The Lancet is the foundational 1-on-1 trial. 30 patients with severe refractory IBS randomized to 7 sessions of 1-on-1 gut-directed hypnotherapy versus supportive psychotherapy plus placebo. The hypnotherapy arm showed dramatic and statistically significant symptom improvement on every measured dimension. Follow-up data in subsequent Whorwell publications (notably the 1987 BMJ follow-up cohort) suggested benefit persisted at 18 months prospective and informally up to 5 years. The trial established that 1-on-1 Manchester Protocol hypnotherapy works in severe refractory IBS. The small sample (n=30) is the principal limitation. For the granular breakdown of Whorwell 1984, see the Whorwell 1984 RCT deep dive.

Gonsalkorale and colleagues 2003 in Gut is the largest single dataset in the field. A clinical audit of 250+ consecutive IBS patients treated with 1-on-1 Manchester Protocol hypnotherapy at the Withington Hospital service in Manchester, reporting 71 percent end-of-treatment response on validated symptom and quality-of-life scoring. A follow-up audit reported approximately 81 percent of responders maintained their gains at median 5-year follow-up. Not an RCT; no control arm. But the largest real-world dataset and the longest follow-up in the literature.

Moser 2013 in the American Journal of Gastroenterology is the principal modern RCT, with group format, 100 patients, active matched-attention control, and 15-month prospective follow-up. The 60 percent responder rate at 15 months is in roughly the same magnitude range as the 1-on-1 Manchester Protocol audit responder rates, despite being delivered in a group format. This is the strongest implicit evidence that group format can produce magnitude of benefit comparable to 1-on-1 format, though the trials are not directly head-to-head and the populations differ.

Peters 2016 in Aliment Pharmacol Ther is the 1-on-1 hypnotherapy versus low-FODMAP comparison trial. 74 patients across three arms, 6-month follow-up, equivalence between hypnotherapy and low-FODMAP at 6 weeks and 6 months. The 1-on-1 hypnotherapy arm used an adapted Manchester Protocol delivered in 6 sessions. For the full breakdown, see the Peters 2016 deep dive.

Reading these together. The 1-on-1 literature establishes the foundational efficacy of the Manchester Protocol family (Whorwell 1984), the scale of the response rate in real-world clinical settings (Gonsalkorale 2003), and the equivalence with the most evidence-backed dietary intervention (Peters 2016). The group-format literature, anchored principally by Moser 2013, establishes that a group adaptation of the protocol family can produce responder rates of roughly comparable magnitude with the longest prospective RCT follow-up in the field.

What I would tell a patient asking which format is 'better.' Honestly, the literature does not give a clear answer because the head-to-head trial has not been done. What we have is a coherent picture in which both formats produce meaningful, durable benefit in IBS populations. The group format is cheaper, more standardized, and is the format with the strongest single long-term RCT (Moser 2013). The 1-on-1 format is more individualized, more widely available in private practice (especially in Canada), and is the format with the foundational mechanism RCT (Whorwell 1984) and the largest real-world dataset (Gonsalkorale 2003). For most people, the practical choice is determined by what is locally available, what their schedule allows, and whether they want individualization or are comfortable in a small group setting.

Honest limitations (sample, group vs individual, follow-up dropout)

Any responsible read of Moser 2013 has to hold the trial's limitations alongside the headline findings. The limitations are typical for this literature, but they are real, and a research-aware reader is right to weigh them.

Sample size is moderate, not large. 100 patients total, split roughly 64 to the experimental arm and 36 to the active control arm under 2:1 randomization. That is enough to detect a large effect like the between-arm difference Moser reported at 15 months, but it is not enough to characterize subgroups with confidence. Whether benefit at 15 months differs by IBS subtype (IBS-C, IBS-D, IBS-M), by baseline severity, by age, by sex, or by prior treatment history is not robustly answerable from a 100-patient trial.

Group format, not 1-on-1. This is the most important generalizability issue for North American private-practice patients in 2026. Most gut-directed hypnotherapy in Canadian private practice is delivered 1-on-1, not in 6 to 10 person groups. The 60 percent responder rate at 15 months was generated by a specific group-format protocol with shared induction, group-paced visualization, and standardized home audio. A patient receiving 1-on-1 hypnotherapy is receiving a related but methodologically distinct intervention, and the Moser 2013 numbers do not transfer directly without that caveat.

The 2:1 randomization is unusual. Modern RCT methodology typically uses 1:1 randomization to maximize statistical power on between-arm comparison. The Moser group chose 2:1 to concentrate power on detecting within-arm effects in the experimental arm. The cost is that the control arm (n approximately 36) is small. Estimates of the control arm responder rate are less precise than they would be under 1:1 randomization. The between-arm difference is real and significant, but the confidence interval on 'how much better is hypnotherapy than active control specifically' is wider than it would be in a 1:1 trial.

Refractory population enrichment cuts both ways. Restricting to patients who had already failed at least one year of standard medical treatment makes the responder rate more clinically meaningful (the intervention is being asked to do something harder). But it also means the responder rate may be inflated for two subtle reasons. First, refractory patients have higher baseline symptom severity, leaving more room to show improvement. Second, refractory patients may be more motivated to engage with a novel protocol, increasing adherence and therapeutic alliance. Both effects argue that the 60 percent figure is a ceiling estimate for refractory populations and should not be directly generalized to mild or treatment-naive IBS.

Dropout at 15 months reduced the analyzable sample. Like most long-follow-up trials, Moser 2013 lost some patients between the 3-month and 15-month assessments. The dropout was higher in the active control arm than the experimental arm. Differential dropout is a recognized methodological concern because the patients who drop out may differ systematically from the patients who stay (for example, control arm patients who did not benefit may be more likely to drop out and seek other treatments). The Moser group reported intention-to-treat analyses to address this, but no statistical correction fully eliminates the concern.

Single-center, single-team. The trial was conducted at one site (Medical University of Vienna) by one clinical and research team. Whether the responder rates would replicate at other sites with different clinician training, different patient demographics, and different baseline care patterns is not established by a single-center trial. The Vienna group are recognized experts in the gut-directed protocol; less-experienced sites may produce smaller effects.

Active control was supportive talks, not waitlist or no-treatment. This is actually a strength rather than a limitation. By comparing hypnotherapy against an active matched-attention control (10 sessions of supportive talks with equivalent group size, equivalent clinician time, equivalent home audio), the trial isolates the specific effect of hypnotic technique from the non-specific effects of attention, group, and structure. Many earlier IBS hypnotherapy trials used waitlist or no-treatment controls, which inflate apparent effect size by including all the attention effects in the experimental arm only. Moser 2013's active control design is methodologically more conservative and the between-arm differences are correspondingly more credible.

None of these limitations mean Moser 2013 is a bad trial. The opposite: it is the strongest single long-term RCT in the gut-directed hypnotherapy literature, the methodology is conservative on the most important dimension (active matched-attention control), and the 15-month durability finding has not been superseded by a larger or longer trial in the decade since publication. The limitations mean it is one trial, not a meta-analysis, and that it tested one specific format on one specific refractory population at one site.

What this means for someone considering hypnotherapy now

If you are reading Moser 2013 because you are deciding whether to try gut-directed hypnotherapy, here is how I would talk through the implications with a patient in my own practice.

The 15-month durability finding is the part that actually matters for the decision. Most short-term IBS treatments produce some benefit during the treatment window. The clinically relevant question is whether the benefit persists after the treatment stops. Moser 2013 is the principal RCT evidence that gut-directed hypnotherapy benefit persists at 15 months in a refractory population. This is the part of the trial that should weigh most heavily in the decision.

Match expectations to the responder rate, not to the headline. Roughly 60 percent of refractory IBS patients met the responder threshold at 15 months in the hypnotherapy arm. Roughly 25 percent did so in the active control arm. The between-arm difference is real and clinically meaningful. The absolute responder rate is not 100 percent. Some patients in the hypnotherapy arm did not meet the responder threshold. A reasonable expectation is something like 'I have a roughly six-in-ten chance of meaningful, durable symptom improvement if I am similar to the trial population and follow the protocol carefully.' That is a good expectation. It is not the same as 'I will be symptom-free.'

Format you receive will probably not be the format Moser tested. Most private-practice gut-directed hypnotherapy in Canada is delivered 1-on-1, not in 6 to 10 person groups. The 1-on-1 format is supported by Whorwell 1984, Gonsalkorale 2003, and Peters 2016 within the same protocol family, and the cross-trial implication is that magnitude of benefit is roughly comparable, but you should know that you are receiving a related intervention rather than the exact intervention Moser tested. If you specifically want the Moser format, ask your prospective clinician whether they offer group programs.

Refractory status of the trial population may overstate response in mild IBS. If you have newly-diagnosed mild IBS that responds to first-line interventions, you are not the trial population. Your baseline severity is lower, and proportionally, the magnitude of improvement that counts as 'responder' on the IBS Impact Scale is harder to achieve from a lower starting point. The 60 percent number is anchored in a hard-to-treat refractory population.

Confirm protocol and credentials. The Moser trial used a named protocol (group adaptation of the Manchester Protocol family) delivered by clinicians trained in gut-directed hypnotherapy. The evidence base sits inside specific protocols, not in general hypnotic technique. Confirm any practitioner you book uses a named protocol (Manchester, North Carolina, or a documented adaptation) and ideally holds ARCH credentials. ARCH (Association of Registered Clinical Hypnotherapists of Canada) is Canada's most stringent voluntary professional body for clinical hypnotherapy. ARCH-credentialed practitioners working from a named protocol are the high end of the Canadian distribution.

Cost in Canada. At Calgary Gut Hypnotherapy, the full protocol typically runs 6 to 8 sessions at $220 to $350 per session, with a 3-session minimum commitment ($660 to $1,050). 1-on-1 format. Most other ARCH-credentialed gut-specialized clinicians in Canada price within the same range. A 10-session group program comparable to Moser 2013 would be cheaper per session in principle but is uncommon in Canadian private practice; it is more often found in academic hospital settings or research programs.

Insurance honest section. Hypnotherapy isn't directly covered by Canadian provincial health plans or most extended health benefit plans. Hypnotherapy isn't a regulated profession in Alberta. Some clients get reimbursement through their employer's Wellness Spending Account (WSA) under categories like 'stress management' or 'mental wellness'. WSAs are different from Health Spending Accounts (HSAs), which follow strict CRA medical-expense rules that exclude practitioners who aren't on a provincial regulated list. Always check with your specific plan whether RCH services qualify.

This is not medical care, not psychotherapy, and not a substitute for working with your gastroenterologist. Gut-directed hypnotherapy is a structured non-pharmacological intervention with RCT support. It is not a diagnostic process. It is not a substitute for appropriate medical workup, ruling out organic disease, or following your physician's pharmacological recommendations. For any medical question about your symptoms, consult your physician.